Reaktion #309489

ord-9442d87d091e43cd89e3325c554c04ff

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Sonstigewhich was evacuated
  2. 2
    workup.ADDITIONFully degassed DMF (1.5 mL) was added
  3. 3
    SonstigeThe tube was placed in an oil bath at 115° C.
  4. 4
    workup.ADDITIONThe reaction mixture was poured into an ethyl acetate/brine mixture
  5. 5
    Extraktionextracted with ethyl acetate
  6. 6
    TrocknenCombined organics were dried over magnesium sulfate
  7. 7
    Filtrationfiltered
  8. 8
    Einengenconcentrated in vacuo
  9. 9
    Sonstigepurified via reverse phase HPLC (10-42% acetonitrile/water gradient, 0.05% trifluoroacetic acid modifier)

Vorschrift

tert-Butyl 4-[2-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-2-hydroxyethyl]piperazine-1-carboxylate (65 mg, 0.138 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (58 mg, 0.28 mol), Pd2(dba)3 (6 mg, 0.007 mmol), (tBu3)PBF4 (4 mg, 0.014 mmol), and potassium fluoride (27 mg, 0.46 mmol) were combined in a sealed tube which was evacuated and backfilled with argon three times. Fully degassed DMF (1.5 mL) was added. The tube was placed in an oil bath at 115° C. and stirred for 19 hours. The reaction mixture was poured into an ethyl acetate/brine mixture and extracted with ethyl acetate. Combined organics were dried over magnesium sulfate, filtered, concentrated in vacuo, and purified via reverse phase HPLC (10-42% acetonitrile/water gradient, 0.05% trifluoroacetic acid modifier) to afford the title compound. 1H NMR (600 MHz, CDCl3) δ 9.00 (d, 1H); 8.55 (d, 1H); 8.23 (d, 1H); 7.91 (s, 1H); 7.80 (s, 1H); 7.76 (dd, 1H); 7.60 (d, 1H); 7.34 (d, 1H); 7.23 (d, 1H); 4.95 (d, 1H); 3.98 (s, 3H); 3.56-3.51 (m, 4H); 2.78-2.53 (m, 6H); 1.46 (s, 9H). Hydroxyl proton was not observed. LRMS (APCI) calc'd for (C29H34N5O4) [M+H]+, 516.3; found 516.3.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08207186B2uspto-grants-2012_06